Trial Profile
Phase II Trial of High Dose Lenalidomide in Patients With MDS and AML With Trilineage Dysplasia (AML-TLD)
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 25 Oct 2018
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary)
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Therapeutic Use
- 08 Dec 2015 Results (n=27), presented at the 57th Annual Meeting and Exposition of the American Society of Hematology.
- 28 Mar 2009 New trial record